**Pharmaceutical Sales:** 70%
**Biotechnology Sales:** 20%
**Health Products Sales:** 10%

**TOP 3 Markets:**

1. **South Korea:** 50%
2. **China:** 25%
3. **USA:** 15%

Dong-A ST Co., Ltd. generates the majority of its sales from the pharmaceutical sector, followed by biotechnology and health products. The domestic market in South Korea is the largest revenue contributor, followed by China and the USA. These markets are crucial for the company due to their size and growth opportunities in the healthcare sector.

**Production Sites:** Headquarters in Seoul, South Korea; several production facilities in South Korea.

Dong-A ST Co., Ltd., a leading pharmaceutical company in South Korea, mainly produces its products in South Korea. The headquarters is located in Seoul, and the company operates multiple production facilities in the country. These sites are strategically positioned to optimize production efficiency and logistics.

The company is known for its research and development in the field of pharmacy and continuously invests in modernizing and expanding its production capacities to meet the increasing market demands.

**Focus on Research and Development:** Increase in R&D budget by 20% (2025)

**International Expansion:** Planned market entries in three new countries (by 2027)

Dong-A ST Co., Ltd. is pursuing a growth strategy that heavily emphasizes research and development. The company increased its R&D budget by 20% in 2025 to accelerate the development of new drugs and therapies. These investments aim to expand the product pipeline and bring innovative solutions to the market.

In addition, Dong-A ST plans to expand its international presence. Market entries in three new countries are planned by 2027 to increase revenue and reduce dependence on the domestic market. These steps are intended to position the company more strongly in the global pharmaceutical market.

**Main raw materials:** Pharmaceutical active ingredients, chemicals

**Import countries:** China, India, Germany

Dong-A ST Co., Ltd., a leading company in the pharmaceutical industry, mainly imports pharmaceutical active ingredients and special chemicals needed for the production of their products.

China and India are the main suppliers of pharmaceutical active ingredients, as these countries have a well-developed infrastructure for the production of these materials. Germany supplies specialized chemicals and technologies that are crucial for the research and development of new drugs.

This import strategy enables Dong-A ST to offer high-quality products at competitive prices and stay at the forefront of pharmaceutical innovation.

**Market share:** 8% (estimated, 2026)
**R&D expenses:** 12% of revenue (2025)
**Patent portfolio:** Over 150 active patents (2025)

Dong-A ST Co., Ltd. has a significant competitive advantage in the pharmaceutical industry, especially due to its strong investments in research and development, which account for about 12% of revenue. This enables the company to continuously develop and launch innovative products to the market.

The company holds an extensive patent portfolio with over 150 active patents, further strengthening its position in the market and making it difficult for new competitors to enter. These patents not only protect existing products but also foster the development of new drugs.

In addition, Dong-A ST has an estimated market share of 8%, indicating a solid market presence. Together, these factors give the company a clear competitive edge in a fiercely competitive market.

**Institutional Investor Share:** Estimated at around 40% (2026)

**Insider Purchases/Sales:** No significant transactions reported (2026)

The institutional investor share in Dong-A ST Co., Ltd. is estimated to be around 40%. This estimate is based on typical ownership levels for companies of this size and industry in South Korea.

Regarding insider transactions, no significant purchases or sales by insiders were reported in 2026. This could indicate that the management has confidence in the current corporate strategy or that there are no significant changes in the ownership structure.

**Market share of Dong-A ST Co., Ltd.:** Estimate: 3-5% (2026)

**Top 5-10 companies by market share:**

1. **Samsung BioLogics** - Market share: 15-18%
2. **Celltrion** - Market share: 12-15%
3. **Hanmi Pharmaceutical** - Market share: 8-10%
4. **LG Chem (Life Sciences Division)** - Market share: 6-8%
5. **SK Biopharmaceuticals** - Market share: 5-7%
6. **Dong-A ST Co., Ltd.** - Market share: 3-5%
7. **Daewoong Pharmaceutical** - Market share: 3-5%
8. **Yuhan Corporation** - Market share: 2-4%
9. **GC Pharma** - Market share: 2-4%
10. **Kolon Life Science** - Market share: 1-3%

**Moat of Dong-A ST Co., Ltd.:**

Dong-A ST Co., Ltd. has a moderate moat, mainly based on its established brand recognition and a solid product pipeline. The company benefits from a strong presence in the Korean market and a diversified product portfolio ranging from prescription drugs to OTC products.

In comparison to its larger competitors like Samsung BioLogics and Celltrion, which have significant resources in research and development as well as international expansion, Dong-A ST's moat is less pronounced. These companies have a significant competitive advantage through their innovation capabilities and global reach.

In summary, Dong-A ST Co., Ltd. operates in a highly competitive market where larger companies dominate through their economies of scale and R&D investments. To strengthen its moat, Dong-A ST could invest in strategic partnerships and innovations to enhance its competitive position.

**Revenue Growth:** 8.5% (2025)
**R&D Expenses:** 12% of revenue (2025)
**Market Share in Korea:** 15% (2025)

Dong-A ST Co., Ltd. shows a solid revenue growth of 8.5% in 2025, attributed to a strong product pipeline and successful market launches. The company continues to invest heavily in research and development, with expenses accounting for 12% of revenue. This indicates a strategic focus on developing innovative products and remaining competitive in the long term.

The 15% market share in Korea indicates that Dong-A ST holds a significant position in the domestic market. This could be an indicator of further growth potential, especially if the company expands its international presence.

Overall, these factors suggest that Dong-A ST Co., Ltd. could be a promising investment, especially for investors interested in long-term growth and valuing innovation.

**Dividend Yield:** 2.5% (estimated for 2026)

**Dividend History:** Continuous payout since 2018

Dong-A ST Co., Ltd. has pursued a consistent dividend policy in recent years. The dividend yield for 2026 is estimated to be around 2.5%, based on the latest available financial data and past payout policy.

The company has regularly distributed dividends since 2018, indicating a reliable dividend policy. This continuity demonstrates the company's commitment to providing its shareholders with a stable return. Analysts expect that Dong-A ST will continue its dividend policy in the coming years, unless significant negative market changes occur.